Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer

Japanese Journal of Clinical Oncology

Volumn 36, Issue 6, 2006, Pages 344-350

  Lee, Kyung Hun ^a   Han, Sae Won ^a   Hwang, Pil Gyu ^a   Oh, Do Youn ^b   Kim, Dong Wan ^a,b   Chung, Doo Hyun ^a   Im, Seock Ah ^a,b   Kim, Tae You ^a,b   Heo, Dae Seog ^a,b   Bang, Yung Jue ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Akt; EGFR; Erk; K ras; Mutation

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NAVELBINE; PACLITAXEL; PARAFFIN; PLATINUM DERIVATIVE; PROTEIN KINASE B;

ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DNA SEQUENCE; DRUG RESPONSE; EXON; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; THORAX RADIOGRAPHY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DNA MUTATIONAL ANALYSIS; GENES, ERBB-1; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MUTATION; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 33745903861     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl039     Document Type: Article

References (28)

1. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 2003;290:2149-58.
2. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
3. Lee DH, Han JY, Lee HG, Lee JJ, Lee EK, Kim HY, et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 2005;11:3032-27.
4. Kasahara K, Kimura H, Yoshimoto A, Sone T, Shibata K, Ishiura Y, et al. A phase II study of gefitinib monotherapy for chemotherapy-naive patients with non-small cell lung cancer. Proc Am Soc Clin Onc 2005;23 (abstr 7074).
5. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004;22:785-94.
6. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 2004;22:777-84.
7. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
8. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
9. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-11.
10. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-23.
11. Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005;11:1167-73.
12. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
13. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195-203.
14. Yang SH, Mechanic LE, Yang P, Landi MT, Bowman ED, Wampfler J, et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2005;11:2106-10.
15. Kim KS, Jeong JY, Kim YC, Na KJ, Kim YH, Ahn SJ, et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 2005;11:2244-51.
16. Han SW, Kim TY, Huang PG, Jeong S, Kim J, Choi IS, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-501.
17. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23: 2513-20.
18. Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 2005; 16:1081-6.
19. Han SW, Jeong S, Choi IS, Kim DW, Chung DH, Im SA, et al. EGFR and K-ras mutations as determinants of gefitinib sensitivity in non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Onc 2005;23 (abstr 7078).
20. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
21. Han SW, Hwang PG, Chung DH, Kim DW, Im SA, Kim YT, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy resistant non-small-cell lung cancer. Int J Cancer 2005;113:109-15.
22. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
23. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, et al. The role of RAS oncogene in survival of patients with lung cancer: A systematic review of the literature with meta-analysis. Br J Cancer 2005;92:131-9.
24. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS Mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:57-61.
25. Rosell R, Gonzalez-Larriba JL, Alberola V, Molina F, Monzo M, Benito D, et al. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: Links between p53 and K-ras gene status and chemosensitivity. Semin Oncol 1995;22:12-8.
26. Chang GC, Hsu SL, Tsai JR, Wu WJ, Chen CY, Sheu GT. Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol 2004;502:169-83.
27. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein dinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001;61:3986-97.
28. Shah A, Swain WA, Richardson D, Edwards J, Stewart DJ, Richardson CM, et al. Phospho-Akt expression is associated with a favorable outcome in non-small cell lung cancer. Clin Cancer Res 2005;11:2930-6.